XPH - ETF AI Analysis
Top Page
SPDR S&P Pharmaceuticals ETF (XPH)
Rating:59Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown positive returns so far this year and over the past month, indicating recent strength in its portfolio.
Top Holdings With Strong Gains
Several of the largest positions, such as Enliven Therapeutics and Nektar Therapeutics, have delivered strong gains, helping support the fund’s overall results.
Focused Exposure to Health Care
With almost all assets in the health care sector, the fund gives targeted access to pharmaceutical and biotech companies for investors who want concentrated industry exposure.
Negative Factors
Single-Sector Concentration Risk
Because the ETF is heavily focused on health care, it could be hit hard if the pharmaceutical or biotech industry faces setbacks.
Limited Geographic Diversification
The fund invests almost entirely in U.S. companies, offering little protection if the U.S. market or regulatory environment for drugs weakens.
Moderate Expense Ratio
The ETF’s expense ratio is not especially low, which means fees may take a noticeable bite out of long-term returns compared with cheaper index funds.
XPH vs. SPDR S&P 500 ETF (SPY)
AUM349.47M
RegionNorth America
Expense Ratio0.35%
Beta0.78
IssuerSPDR
Inception DateJun 19, 2006
Dividend Yield0.62%
Asset ClassEquity
Index TrackedS&P Pharmaceuticals Select Industry
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume65,134
30 Day Avg. Volume49,212
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
93.29Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering59
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
XPH Summary
SPDR S&P Pharmaceuticals ETF (XPH) is a fund that follows the S&P Pharmaceuticals Select Industry Index, focusing on U.S. drugmakers within the health care sector. It holds a mix of larger and smaller pharmaceutical companies working on new medicines and treatments, including names like Perrigo Company and Axsome Therapeutics. Someone might invest in XPH to bet on long-term growth in health care as populations age and demand for medicines rises, while still spreading money across many stocks instead of picking just one. A key risk is that it is heavily tied to pharmaceutical stocks, which can be volatile and move sharply with drug trial news and regulation changes.
How much will it cost me?The SPDR S&P Pharmaceuticals ETF (XPH) has an expense ratio of 0.35%, which means you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is a sector-focused fund, which often requires more active management compared to broad-market index funds.
What would affect this ETF?The SPDR S&P Pharmaceuticals ETF (XPH) could benefit from increasing global health care needs, advancements in biotechnology, and demographic trends such as aging populations, which drive demand for innovative drugs and treatments. However, it may face challenges from regulatory changes, patent expirations, or pricing pressures in the pharmaceutical industry, as well as broader economic conditions like rising interest rates that could impact funding for smaller companies in its portfolio. Its focus on U.S.-based pharmaceutical firms makes it sensitive to domestic health care policies and market dynamics.
XPH Top 10 Holdings
XPH is a pure play on U.S. pharmaceuticals, and its story right now is all about high-risk, high-reward drug developers. Liquidia and Corcept are doing the heavy lifting, with rising momentum fueled by product launches and solid demand, while Axsome and Jazz add steady, if sometimes bumpy, growth to the mix. On the flip side, Omeros is clearly dragging the fund, and MBX and Enliven look more like question marks than anchors, reflecting the early-stage, cash-burning side of this pharma-heavy portfolio.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Corcept Therapeutics | 4.20% | $14.68M | $8.39B | 9.66% | 76 Outperform | |
| Organon | 3.79% | $13.26M | $3.51B | 33.56% | 53 Neutral | |
| Liquidia Technologies | 3.07% | $10.73M | $5.80B | 395.67% | 57 Neutral | |
| Axsome Therapeutics | 2.80% | $9.79M | $12.68B | 138.84% | 57 Neutral | |
| Definium Therapeutics | 2.26% | $7.91M | $2.53B | 214.05% | 40 Neutral | |
| Jazz Pharmaceuticals | 2.25% | $7.85M | $14.42B | 107.81% | 64 Neutral | |
| Harmony Biosciences Holdings | 2.23% | $7.81M | $2.05B | 0.97% | 81 Outperform | |
| Amneal Pharmaceuticals | 2.19% | $7.64M | $4.89B | 105.28% | 58 Neutral | |
| Enliven Therapeutics | 2.19% | $7.64M | $2.25B | 88.73% | 36 Underperform | |
| Royalty Pharma | 2.12% | $7.40M | $31.40B | 60.12% | 79 Outperform |
XPH Technical Analysis
Positive
―
Price Trends
57.65
Positive
56.64
Positive
53.82
Positive
Market Momentum
0.38
Negative
62.41
Neutral
85.50
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XPH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 57.63, equal to the 50-day MA of 57.65, and equal to the 200-day MA of 53.82, indicating a bullish trend. The MACD of 0.38 indicates Negative momentum. The RSI at 62.41 is Neutral, neither overbought nor oversold. The STOCH value of 85.50 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XPH.
XPH Peer Comparison
Comparison Results
Performance Comparison
XPH
SPDR S&P Pharmaceuticals ETF
60.27
18.94
45.83%
IHF
iShares U.S. Healthcare Providers ETF
―
―
―
IHE
iShares U.S. Pharmaceuticals ETF
―
―
―
FXH
First Trust Health Care AlphaDEX Fund
―
―
―
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
PJP
Invesco Dynamic Pharmaceuticals ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents